The Eli Lilly MDR-TB Partnership: Creating Private and Public Value Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

In 2003, the pharmaceutical manufacturer Eli Lilly established MDR-TB Partnership in the fight against MDR-TB, TB. An estimated 450,000 new cases were registered in the year, mainly in China, India and Russia. Partnership, an alliance of 14 public and private organizations, tried to pass technology to increase the supply of drugs that could treat MDR-TB, and training of health workers to develop successful strategies for diagnosis and treatment, as well as to publicly support the proper treatment of MDR-TB through community support , the protection of patients' rights and workplace awareness. Partnership was the organizational success, but in reality the technology transfer across borders of both organizations and countries was a serious problem. Furthermore, it was difficult for Lilly, large pharmaceutical companies, its credibility with NGOs whose focus was the treatment of patients suffering from MDR-TB in the remote areas of the world. Initial investment Lilly $ 70 million was not enough, and their commitment was subsequently increased to $ 120 million. The case allows for discussion of issues, including: What is the social value was created and how it will be supported initiatives Lilly? What are the risks of technology transfer of pharmaceutical partners in different countries? What were the motives of the partners in this case? What can the Minister of Health in each country to make the partnership more effective? What are the benefits and risks to the company growth Lilly to initiate and manage the complexity of this partnership? Have the lessons of partnership Lilly, which can be applied to other global health challenges? HKS Case Number 1871.0 "Hide
by Jessica Droste Yagan 28 pages. Publication Date: 05 Oct 2007. Prod. #: HKS239-PDF-ENG